Lymphocytic Extracellular Signal-Regulated Kinase Dysregulation in Autism Spectrum Disorder.

Researchers studied a specific cellular pathway (ERK1/2) in blood samples from 67 people with autism compared to control groups. They found that people with autism had faster activation of this pathway, especially younger children. This faster response was linked to more social difficulties. The findings suggest differences in how cells respond to signals in autism, which could help us better understand the condition.

This study examined ERK1/2 signaling pathway activity in blood cells from 67 individuals with autism (3-25 years), compared to typically developing controls, developmental disability controls, and individuals with Fragile X syndrome. Using flow cytometry analysis, researchers found that people with autism showed significantly more rapid ERK1/2 activation (5.81 minutes vs 6.4-6.78 minutes in controls). This faster activation correlated with increased social impairment across all groups and was most pronounced in younger children. ERK1/2 is important for brain development and neuroplasticity, suggesting potential biomarker utility and mechanistic insights into autism.

ERK1/2 activation kinetics may serve as a potential biomarker for autism, particularly in younger children. The correlation with social impairment suggests clinical utility for assessment and monitoring. However, further research is needed to validate these findings and determine clinical applications.

Study design not specified in abstract. Limited information about participant characteristics beyond age ranges. Cross-sectional design cannot establish causality. Unclear if findings in blood cells reflect brain activity. Need for replication in larger samples.

Extracellular signal-regulated kinase (ERK1/2) is a conserved central intracellular signaling cascade involved in many aspects of neuronal development and plasticity. Converging evidence support investigation of ERK1/2 activity in autism spectrum disorder (ASD). We previously reported enhanced baseline lymphocytic ERK1/2 activation in autism, and now we extend our work to investigate the early phase kinetics of lymphocytic ERK1/2 activation in idiopathic ASD. Study participants included 67 individuals with ASD (3-25 years of age), 65 age- and sex-matched typical developing control (TDC) subjects, and 36 age-, sex-, and IQ-matched developmental disability control (DDC) subjects matched to those with ASD and IQ <90.

We completed an additional analysis comparing results from ASD, TDC, and DDC groups with data from 37 individuals with Fragile X syndrome (FXS). All subjects had blood lymphocyte samples analyzed by flow cytometry following stimulation with phorbol ester and sequentially analyzed for ERK1/2 activation (phosphorylation) at several time points. The ASD group (mean = 5.81 minutes; SD = 1.5) had a significantly lower (more rapid) mean ERK1/2 Tactivation value than both the DDC group (mean = 6.78 minutes; SD = 1.6; p = .00078) and the TDC group (mean = 6.4 minutes; SD = 1.5; p = .025). More rapid ERK1/2 Tactivation times did correlate with increased social impairment across all study groups including the ASD cohort.

Differences in ERK1/2 Tactivation were more pronounced in younger than in older individuals in the primary analysis. The ASD group additionally had more rapid activation times than the FXS group, and the FXS group activation kinetics did not differ from those of the TDC and DDC groups. Our findings indicate that lymphocytic ERK1/2 activation kinetics are dysregulated in persons with ASD, marked by more rapid early phase activation. Group differences in ERK1/2 activation kinetics appear to be driven by findings from the youngest children analyzed.

We worked to ensure sex and gender balance in the recruitment of human participants. We actively worked to promote sex and gender balance in our author group. The author list of this paper includes contributors from the location and/or community where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.